DE69531403D1 - Allosterische modulatoren des nmda-rezeptors - Google Patents

Allosterische modulatoren des nmda-rezeptors

Info

Publication number
DE69531403D1
DE69531403D1 DE69531403T DE69531403T DE69531403D1 DE 69531403 D1 DE69531403 D1 DE 69531403D1 DE 69531403 T DE69531403 T DE 69531403T DE 69531403 T DE69531403 T DE 69531403T DE 69531403 D1 DE69531403 D1 DE 69531403D1
Authority
DE
Germany
Prior art keywords
nmda receptor
allosteric modulators
compositions
methods
receptor function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531403T
Other languages
English (en)
Inventor
Maria-Luisa Maccecchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annovis Inc
Original Assignee
Bearsden Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/323,436 external-priority patent/US5830998A/en
Application filed by Bearsden Bio Inc filed Critical Bearsden Bio Inc
Application granted granted Critical
Publication of DE69531403D1 publication Critical patent/DE69531403D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
DE69531403T 1994-10-14 1995-10-13 Allosterische modulatoren des nmda-rezeptors Expired - Lifetime DE69531403D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/323,436 US5830998A (en) 1992-09-28 1994-10-14 Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US08/413,490 US5854217A (en) 1992-09-28 1995-03-30 Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
PCT/US1995/013037 WO1996011698A1 (en) 1994-10-14 1995-10-13 Allosteric modulators of the nmda receptor

Publications (1)

Publication Number Publication Date
DE69531403D1 true DE69531403D1 (de) 2003-09-04

Family

ID=26983959

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531403T Expired - Lifetime DE69531403D1 (de) 1994-10-14 1995-10-13 Allosterische modulatoren des nmda-rezeptors

Country Status (7)

Country Link
US (5) US5854217A (de)
EP (1) EP0785793B1 (de)
JP (1) JP3273792B2 (de)
AT (1) ATE245993T1 (de)
CA (1) CA2202513C (de)
DE (1) DE69531403D1 (de)
WO (1) WO1996011698A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5763393A (en) * 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
WO1998003541A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
JP2002513380A (ja) * 1996-07-22 2002-05-08 コグネティックス・インコーポレイテッド コナントキンの使用
US6063819A (en) * 1997-02-21 2000-05-16 Cypros Pharmaceutical Corp. Neuroprotective poly-guanidino compounds which block presynaptic N and P/Q calcium channels
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
JP2002502616A (ja) * 1998-02-10 2002-01-29 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション イモガイγ−カルボキシラーゼを精製しアッセイする方法
WO2001018033A1 (en) * 1999-09-10 2001-03-15 University Of Utah Research Foundation Gamma-carboxyglutamate containing conopeptides
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
DE60131033T2 (de) * 2000-08-25 2008-07-17 Research Corp. Technologies, Inc., Tucson Verwendungen von antikonvulsiven Aminosäure zur Behandlung bipolarer Erkrankungen
WO2002072005A2 (en) * 2001-03-07 2002-09-19 University Of Utah Research Foundation Linear y-carboxyglutamate rich conotoxins
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20070197583A1 (en) * 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en) * 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
AU2003901325A0 (en) 2003-03-21 2003-04-03 Stephen Locarnini Therapeutic, prophylactic and diagnostic agents
EP1667516A4 (de) 2003-08-29 2009-11-11 Inst Medical W & E Hall Verfahren zur auswahl von tiermodellen von tieren, die mutagenese unterzogen worden sind, und verwendung von myb-transkriptionsfaktoren zum screening
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
JP2007516984A (ja) 2003-12-24 2007-06-28 ザ ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 治療用物質およびそのための用途
CA2566549C (en) 2004-05-12 2014-01-14 The Walter And Eliza Hall Institute Of Medical Research A method for isolating mammary stem cells
DK2407484T3 (en) 2005-06-24 2016-09-05 The Walter And Eliza Hall Inst Of Medical Res Therapeutic pro-apoptotic BH3-like molecules, and methods of generating and / or selecting those
CN100341566C (zh) * 2005-12-29 2007-10-10 中国人民解放军军事医学科学院生物工程研究所 芋螺多肽衍生物用于制备戒毒药物的用途
NZ569697A (en) 2006-01-20 2012-01-12 Women S & Children S Health Res Inst Method of treatment, prophylaxis and diagnosis of pathologies of the bone by the modulation of GPC3
EP2051726B1 (de) 2006-07-18 2018-04-18 University of Utah Research Foundation Verfahren zur behandlung von schmerzen und screening von analgetischen verbindungen
US20090291150A1 (en) * 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
BRPI0902039B8 (pt) 2009-06-09 2021-05-25 Anhanguera Educacional Ltda composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais
EP2260864A1 (de) 2009-06-10 2010-12-15 University of Melbourne Therapeutische Anwendungen
CA2803029A1 (en) 2010-06-23 2011-12-29 Monash University Constrained immunogenic compositions and uses therefor
WO2012016290A1 (en) 2010-08-04 2012-02-09 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Modified hepatitis c virus proteins
WO2012068637A1 (en) 2010-11-26 2012-05-31 The Macfarlane Burnet Institute For Medical Research And Public Health Compositions and methods
CA2913993A1 (en) 2013-05-31 2014-12-04 University Of Utah Research Foundation Conotoxin peptides, pharmaceutical compositions and uses thereof
WO2016149248A1 (en) 2015-03-15 2016-09-22 Emory University N-methyl-d-aspartate receptor (nmdar) potentiators, pharmaceutical compositions, and uses related thereto
US10314320B2 (en) 2015-03-20 2019-06-11 Meltz, LLC Systems for controlled liquid food or beverage product creation
US10111554B2 (en) 2015-03-20 2018-10-30 Meltz, LLC Systems for and methods of controlled liquid food or beverage product creation
EP3368551B1 (de) 2015-10-27 2023-07-12 The University Of Queensland Ein modifiziertes epha4-polypeptid
WO2017109756A2 (es) * 2015-12-22 2017-06-29 Universidad Nacional De Colombia Péptidos sintéticos moduladores del receptor nmda
WO2018068090A1 (en) 2016-10-12 2018-04-19 Glycan Biosciences Llc Therapeutic agents and methods of producing same
AU2017344755B2 (en) * 2016-10-20 2023-02-02 Memphasys Limited Electrophoresis device
US20230127490A1 (en) * 2016-10-20 2023-04-27 Memphasys Limited Electrophoresis device
JP2020517400A (ja) 2017-04-27 2020-06-18 コミティア，インク． 遠心分離抽出のための方法および本方法を実行するために好適な装置
US11724849B2 (en) 2019-06-07 2023-08-15 Cometeer, Inc. Packaging and method for single serve beverage product
WO2021137245A1 (en) * 2020-01-05 2021-07-08 Technion Research & Development Foundation Limited Conus-based toxin peptides, nucleic acids encoding same and uses thereof in modulating nmda receptors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051413A (en) 1986-02-13 1991-09-24 Ciba-Geigy Corporation Unsaturated amino acids
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US5049555A (en) 1988-12-19 1991-09-17 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
GB9109007D0 (en) 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
ES2113957T3 (es) 1991-09-09 1998-05-16 Warner Lambert Co Preparacion farmaceutica conteniendo un agente uricosurico y un antagonista de aminoacidos excitadores.
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5432155A (en) 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
DE19543478A1 (de) * 1995-11-22 1997-05-28 Bayer Ag Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
JP2002513380A (ja) * 1996-07-22 2002-05-08 コグネティックス・インコーポレイテッド コナントキンの使用
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection

Also Published As

Publication number Publication date
US6284731B1 (en) 2001-09-04
EP0785793A1 (de) 1997-07-30
US5854217A (en) 1998-12-29
US20030134799A1 (en) 2003-07-17
EP0785793A4 (de) 2000-08-30
EP0785793B1 (de) 2003-07-30
JP3273792B2 (ja) 2002-04-15
US6511963B1 (en) 2003-01-28
ATE245993T1 (de) 2003-08-15
US6110894A (en) 2000-08-29
CA2202513C (en) 2002-08-13
WO1996011698A1 (en) 1996-04-25
JPH10504316A (ja) 1998-04-28
CA2202513A1 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
ATE245993T1 (de) Allosterische modulatoren des nmda-rezeptors
NO986100D0 (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
DK0800519T3 (da) Steroidreceptormodulatorforbindelser og fremgangsmåder
EP0911321A3 (de) Verbindungen zur Behandlung von Osteoporose
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
YU7797A (sh) Kombinovana terapija za osteoporozu
AP9801269A0 (en) Prostaglandin agonists.
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
JO2359B1 (en) Benzathene derivatives as agents for modulation of GABA A receptor
PL338352A1 (en) Derivatives of 1-(n-phenylaminoalkyl)-piperazine substituted at position 2 of its phenyl ring
GB9712966D0 (en) Novel chalcones
DK0923599T3 (da) Fremgangsmåde til fremstilling af 17-estere af 9alfa, 21-dihalogenpregnan-11beta, 17alfa-diol-20-oner
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
BR9812694A (pt) Derivados de aminoalquilfenol e compostos relacionados
BR9714189A (pt) N-(piridinilamino) isoindolinas e compostos relacionados
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
DE69833655D1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie

Legal Events

Date Code Title Description
8332 No legal effect for de